Movatterモバイル変換


[0]ホーム

URL:


SG10201913557TA - Compositions comprising bacterial blautia strains for treating visceral hypersensitivity - Google Patents

Compositions comprising bacterial blautia strains for treating visceral hypersensitivity

Info

Publication number
SG10201913557TA
SG10201913557TASG10201913557TASG10201913557TASG10201913557TASG 10201913557T ASG10201913557T ASG 10201913557TASG 10201913557T ASG10201913557T ASG 10201913557TASG 10201913557T ASG10201913557T ASG 10201913557TASG 10201913557T ASG10201913557T ASG 10201913557TA
Authority
SG
Singapore
Prior art keywords
bacterial
compositions
visceral hypersensitivity
treating visceral
blautia strains
Prior art date
Application number
SG10201913557TA
Inventor
Annick Bernalier-Donadille
Laureen Crouzet
Chloe Habouzit
Original Assignee
4D Pharma Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1603817.6Aexternal-prioritypatent/GB201603817D0/en
Priority claimed from GBGB1612191.5Aexternal-prioritypatent/GB201612191D0/en
Application filed by 4D Pharma PlcfiledCritical4D Pharma Plc
Publication of SG10201913557TApublicationCriticalpatent/SG10201913557TA/en

Links

Classifications

Landscapes

SG10201913557TA2016-03-042017-03-06Compositions comprising bacterial blautia strains for treating visceral hypersensitivitySG10201913557TA (en)

Applications Claiming Priority (3)

Application NumberPriority DateFiling DateTitle
GBGB1603817.6AGB201603817D0 (en)2016-03-042016-03-04Compositions comprising bacterial strains
GBGB1612191.5AGB201612191D0 (en)2016-07-132016-07-13Compositions comprising bacterial strains
GBGB1616022.8AGB201616022D0 (en)2016-07-132016-09-20Compositions comprising bacterial strains

Publications (1)

Publication NumberPublication Date
SG10201913557TAtrue SG10201913557TA (en)2020-02-27

Family

ID=59742619

Family Applications (2)

Application NumberTitlePriority DateFiling Date
SG11201807195VASG11201807195VA (en)2016-03-042017-03-06Compositions comprising bacterial blautia strains for treating visceral hypersensitivity
SG10201913557TASG10201913557TA (en)2016-03-042017-03-06Compositions comprising bacterial blautia strains for treating visceral hypersensitivity

Family Applications Before (1)

Application NumberTitlePriority DateFiling Date
SG11201807195VASG11201807195VA (en)2016-03-042017-03-06Compositions comprising bacterial blautia strains for treating visceral hypersensitivity

Country Status (31)

CountryLink
US (4)US10086022B2 (en)
EP (2)EP3313423B1 (en)
JP (3)JP6441536B2 (en)
KR (1)KR102010207B1 (en)
CN (2)CN108883139B (en)
AU (2)AU2017226831B2 (en)
BR (1)BR112018067689A2 (en)
CA (1)CA3016179C (en)
CO (1)CO2018010459A2 (en)
CY (1)CY1122142T1 (en)
DK (1)DK3313423T3 (en)
EA (1)EA035949B1 (en)
ES (1)ES2731579T3 (en)
HK (1)HK1246670B (en)
HR (1)HRP20191096T1 (en)
HU (1)HUE044051T2 (en)
IL (2)IL261371B (en)
LT (1)LT3313423T (en)
MA (1)MA42560B1 (en)
MD (1)MD3313423T2 (en)
ME (1)ME03487B (en)
MX (2)MX373290B (en)
NZ (1)NZ745678A (en)
PL (1)PL3313423T3 (en)
PT (1)PT3313423T (en)
RS (1)RS58869B1 (en)
SG (2)SG11201807195VA (en)
SI (1)SI3313423T1 (en)
SM (1)SMT201900368T1 (en)
TW (1)TW201733601A (en)
WO (1)WO2017148596A1 (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
GB201112091D0 (en)2011-07-142011-08-31Gt Biolog LtdBacterial strains isolated from pigs
GB201117313D0 (en)2011-10-072011-11-16Gt Biolog LtdBacterium for use in medicine
GB201306536D0 (en)2013-04-102013-05-22Gt Biolog LtdPolypeptide and immune modulation
SMT201800291T1 (en)2014-12-232018-07-174D Pharma Res LimitedPirin polypeptide and immune modulation
SG10201913609PA (en)2014-12-232020-03-304D Pharma Res LtdImmune modulation
SMT201900539T1 (en)2015-06-152019-11-134D Pharma Res LimitedCompositions comprising bacterial strains
EP3360559B1 (en)2015-06-152019-10-234D Pharma Research LimitedCompositions comprising bacterial strains
MA41010B1 (en)2015-06-152020-01-314D Pharma Res Ltd Compositions comprising bacterial strains
MA41060B1 (en)2015-06-152019-11-294D Pharma Res Ltd Compositions comprising bacterial strains
RS59446B1 (en)2015-06-152019-11-294D Pharma Res LtdBlautia stercosis and wexlerae for use in treating inflammatory and autoimmune diseases
CA3005781C (en)2015-11-202019-01-224D Pharma Research LimitedCompositions comprising bacterial strains
GB201520497D0 (en)2015-11-202016-01-064D Pharma Res LtdCompositions comprising bacterial strains
GB201520631D0 (en)2015-11-232016-01-064D Pharma Res LtdCompositions comprising bacterial strains
GB201520638D0 (en)2015-11-232016-01-064D Pharma Res LtdCompositions comprising bacterial strains
GB201612191D0 (en)2016-07-132016-08-244D Pharma PlcCompositions comprising bacterial strains
CA3016179C (en)2016-03-042019-08-134D Pharma PlcCompositions comprising bacterial blautia strains for treating visceral hypersensitivity
KR20250140643A (en)2016-06-142025-09-25베단타 바이오사이언시즈, 인크.Treatment of clostridium difficile infection
US9999641B2 (en)2016-06-142018-06-19Vedanta Biosciences, Inc.Treatment of clostridium difficile infection
TWI802545B (en)2016-07-132023-05-21英商4D製藥有限公司Compositions comprising bacterial strains
GB201621123D0 (en)*2016-12-122017-01-254D Pharma PlcCompositions comprising bacterial strains
EP3606325B1 (en)2017-04-032024-09-04Gusto Global, LLCRational design of microbial-based biotherapeutics
TW201907929A (en)2017-05-222019-03-01英商4D製藥研究有限公司 a composition comprising a bacterial strain
TW201907931A (en)2017-05-242019-03-01英商4D製藥研究有限公司 Composition comprising a bacterial strain
PL3600363T3 (en)2017-06-142021-06-144D Pharma Research LimitedCompositions comprising bacterial strains
WO2018229236A2 (en)2017-06-142018-12-204D Pharma Research LimitedCompositions comprising bacterial strains
LT3638271T (en)2017-06-142021-01-114D Pharma Research Limited COMPOSITIONS INCLUDING BACTERIAL STRAINS
MA50086A (en)2017-09-082020-07-15Evelo Biosciences Inc BACTERIAL EXTRACELLULAR (EV) VESICLES
WO2019243814A1 (en)*2018-06-192019-12-264D Pharma Research LtdDosage form comprising a live biotherapeutic product
JP2021529816A (en)2018-07-162021-11-04フォーディー ファーマ リサーチ リミテッド4D Pharma Research Limited Compositions Containing Bacterial Strains
CN112888447A (en)2018-08-172021-06-01韦丹塔生物科学股份有限公司Methods for reducing dysbacteriosis and restoring microbial flora
JP2022527653A (en)2019-04-032022-06-02フォーディー ファーマ コーク リミテッド How to diagnose a disease
AU2020276670A1 (en)2019-05-102021-12-094D Pharma Research LimitedCompositions comprising bacterial strains
EP4025299A4 (en)*2019-09-052023-08-23Superbrewed Food, Inc.Mixotrophic probiotic compositions and uses thereof in the treatment of bloating
KR102512643B1 (en)*2020-10-282023-03-22에코바이오홀딩스 주식회사Composition for the prevention, improvement or treatment of allergic disease comprising fraction of biosulfur-containing filtrate
AU2023345834A1 (en)*2022-09-202025-03-06Cost-Bry Pty Ltd (trading as BiomeBank)Compositions and methods for reducing endogenous sulphide in inflammatory bowel diseases
WO2025035190A1 (en)*2023-08-162025-02-20Cost-Bry Pty Ltd (trading as BiomeBank)Novel co-cultured microbial consortia

Family Cites Families (356)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
NL154598B (en)1970-11-101977-09-15Organon Nv PROCEDURE FOR DETERMINING AND DETERMINING LOW MOLECULAR COMPOUNDS AND PROTEINS THAT CAN SPECIFICALLY BIND THESE COMPOUNDS AND TEST PACKAGING.
US3817837A (en)1971-05-141974-06-18Syva CorpEnzyme amplification assay
US3939350A (en)1974-04-291976-02-17Board Of Trustees Of The Leland Stanford Junior UniversityFluorescent immunoassay employing total reflection for activation
US3996345A (en)1974-08-121976-12-07Syva CompanyFluorescence quenching with immunological pairs in immunoassays
US4275149A (en)1978-11-241981-06-23Syva CompanyMacromolecular environment control in specific receptor assays
US4277437A (en)1978-04-051981-07-07Syva CompanyKit for carrying out chemically induced fluorescence immunoassay
US4366241A (en)1980-08-071982-12-28Syva CompanyConcentrating zone method in heterogeneous immunoassays
NL8300698A (en)1983-02-241984-09-17Univ Leiden METHOD FOR BUILDING FOREIGN DNA INTO THE NAME OF DIABIC LOBAL PLANTS; AGROBACTERIUM TUMEFACIENS BACTERIA AND METHOD FOR PRODUCTION THEREOF; PLANTS AND PLANT CELLS WITH CHANGED GENETIC PROPERTIES; PROCESS FOR PREPARING CHEMICAL AND / OR PHARMACEUTICAL PRODUCTS.
US4816567A (en)1983-04-081989-03-28Genentech, Inc.Recombinant immunoglobin preparations
US4683202A (en)1985-03-281987-07-28Cetus CorporationProcess for amplifying nucleic acid sequences
DK122686D0 (en)1986-03-171986-03-17Novo Industri As PREPARATION OF PROTEINS
FR2613624B1 (en)1987-04-101990-11-23Roussy Inst Gustave ORAL ADMINISTRATIVE PHARMACEUTICAL COMPOSITION FOR REDUCING THE EFFECTS OF B-LACTAMINES
US5443826A (en)1988-08-021995-08-22Borody; Thomas J.Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli
CA1333564C (en)1988-08-021994-12-20Thomas Julius BorodyTreatment of gastro-intestinal disorders
KR100225087B1 (en)1990-03-231999-10-15한스 발터라벤The expression of phytase in plants
BR9106435A (en)1990-05-091993-05-04Novo Nordisk As CELLULLASE PREPARATION, ENZYME DEMONSTRATING ANDDOGLUCANASE ACTIVITY, ENDOGLUCANASE ENZYME, DNA CONSTRUCTION, CELL EXPRESSION VECTOR, PROCESS FOR PRODUCING AN ENDOGLUCANASE ENZYME, ADDITIVE DETERGENT COMPOSITION, AND PROCESS TO REDUCE THE RATE AT WHICH CELLULOSE CONTAINING TISSUES BECOME ROUGH, PROVIDE COLOR LIGHTENING OF TISSUES CONTAINING COLORED CELLULOSE, PROVIDES A LOCAL COLOR VARIATION OF TISSUES CONTAINING COLORED, AND IMPROVES PULP DRAINAGE PROPERTIES
GB9107305D0 (en)1991-04-081991-05-22Unilever PlcProbiotic
CA2100919A1 (en)1992-07-201994-01-21Takaharu YamamotoSpecies-specific oligonucleotides for bifidobacteria and a method of detection using the same
CA2151154C (en)1992-12-101999-01-26William E. HintzProduction of heterologous proteins in filamentous fungi
US5741665A (en)1994-05-101998-04-21University Of HawaiiLight-regulated promoters for production of heterologous proteins in filamentous fungi
US5599795A (en)1994-08-191997-02-04Mccann; MichaelMethod for treatment of idiopathic inflammatory bowel disease (IIBD)
AUPM823094A0 (en)1994-09-161994-10-13Goodman Fielder LimitedProbiotic compositions
AUPM864894A0 (en)1994-10-071994-11-03Borody, Thomas JuliusTreatment of bowel-dependent neurological disorders
RU2078815C1 (en)1995-01-171997-05-10Московский научно-исследовательский институт эпидемиологии и микробиологии им.Г.Н.ГабричевскогоStrain of bacterium bifidobacterium breve used for preparing the bacterial curative-prophylaxis bifido-containing preparations
JPH08259450A (en)1995-03-171996-10-08Nichinichi Seiyaku KkEnhancer for production of interferon
US6861053B1 (en)1999-08-112005-03-01Cedars-Sinai Medical CenterMethods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
AUPN698495A0 (en)1995-12-061996-01-04Pharma Pacific Pty LtdImproved therapeutic formulation and method
SE508045C2 (en)1996-02-261998-08-17Arla Ekonomisk Foerening Adhesion inhibitors, preparations containing the same and process for their preparation
AUPN881396A0 (en)1996-03-201996-04-18Arnott's Biscuits LimitedEnhancement of microbial colonization of the gastrointestinal tract
WO1997034591A1 (en)1996-03-201997-09-25The University Of New South WalesAlteration of microbial populations in the gastrointestinal tract
AU2152897A (en)1996-03-271997-10-17Novo Nordisk A/SAlkaline protease deficient filamentous fungi
US6033864A (en)1996-04-122000-03-07The Regents Of The University Of CaliforniaDiagnosis, prevention and treatment of ulcerative colitis, and clinical subtypes thereof, using microbial UC pANCA antigens
WO1998043081A1 (en)1997-03-261998-10-01Ligand Pharmaceuticals IncorporatedTreatment of gastrointestinal disease with ppar modulators
SE511524C2 (en)1997-06-021999-10-11Essum Ab Lactobacillus casei rhamnosus strain and pharmaceutical preparation for the control of pathogenic intestinal bacteria
US5925657A (en)1997-06-181999-07-20The General Hospital CorporationUse of PPARγ agonists for inhibition of inflammatory cytokine production
AUPO758297A0 (en)1997-06-271997-07-24Rowe, James BaberControl of acidic gut syndrome
US5951977A (en)1997-10-141999-09-14The United States Of America, As Represented By The Secretary Of AgricultureCompetitive exclusion culture for swine
IT1298918B1 (en)1998-02-202000-02-07Mendes Srl USE OF ARGININE DEIMINASE BACTERIA TO INDUCE APOPTOSIS AND / OR REDUCE AN INFLAMMATORY REACTION AND PHARMACEUTICAL COMPOSITIONS
DE19826928A1 (en)1998-06-171999-12-23Novartis Consumer Health Gmbh Medicines containing viable anaerobic bacteria that inhibit sulfate reduction by sulfate-reducing bacteria
ID29150A (en)1999-01-152001-08-02Entpr Ireland Cs USE OF LACTOBACILLUS SALIVARIUS
US7090973B1 (en)1999-04-092006-08-15Oscient Pharmaceuticals CorporationNucleic acid sequences relating to Bacteroides fragilis for diagnostics and therapeutics
DK1206457T3 (en)1999-08-272004-02-16Lilly Co Eli Biaryl-oxa (thia) zole derivatives and their use as modulators PPAPs
AU781415B2 (en)2000-02-082005-05-19Dsm Ip Assets B.V.Use of acid-stable proteases in animal feed
FR2808689B1 (en)2000-05-112004-09-03Agronomique Inst Nat Rech USE OF HYDROGENOTROPHIC ACETOGENIC STRAINS FOR THE PREVENTION OR TREATMENT OF DIGESTIVE DISORDERS
US20020013270A1 (en)2000-06-052002-01-31Bolte Ellen R.Method for treating a mental disorder
AUPQ899700A0 (en)2000-07-252000-08-17Borody, Thomas JuliusProbiotic recolonisation therapy
JP2004536557A (en)2000-11-272004-12-09ワシントン・ユニバーシティ Method for investigating the effect of symbiotic microflora on mammalian intestine and treatment of gastrointestinal related diseases based on it
DE10101793A1 (en)2001-01-172002-08-01Manfred Nilius Use of SLPI to treat inflammatory bowel disease
EP1227152A1 (en)2001-01-302002-07-31Société des Produits Nestlé S.A.Bacterial strain and genome of bifidobacterium
KR100437497B1 (en)2001-03-072004-06-25주식회사 프로바이오닉Acid-tolerant Lactobacillus reuteri Probio-16 suppressing the growth of pathogenic microorganisms and rotavirus, and Probiotics containing the same
EP1243273A1 (en)2001-03-222002-09-25Societe Des Produits Nestle S.A.Composition comprising a prebiotic for decreasing infammatory process and abnormal activation of non-specific immune parameters
DE60141773D1 (en)2001-04-202010-05-20Inst Systems Biology GREAT SIMILAR RECEPTOR 5-LIGANDS AND USE PROCESS
EP1260227A1 (en)2001-05-232002-11-27Societe Des Produits Nestle S.A.Lipoteichoic acid from lactic acid bacteria and its use to modulate immune responses mediated by gram-negative bacteria, potential pathogenic gram-positive bacteria
PE20030284A1 (en)2001-07-262003-05-01Alimentary Health Ltd BIFIDOBACTERIUM STRAINS
MXPA04001999A (en)2001-09-052004-07-16Vsl Pharmaceuticals IncLactic acid bacteria comprising unmethylated cytosine-guanine dinucleotides for use in therapy.
GB0127916D0 (en)2001-11-212002-01-16Rowett Res InstMethod
JP2005518195A (en)2001-11-272005-06-23ワシントン・ユニバーシティ Therapeutic proteins and therapeutic methods
WO2003053220A2 (en)2001-12-172003-07-03Corixa CorporationCompositions and methods for the therapy and diagnosis of inflammatory bowel disease
US7101565B2 (en)2002-02-052006-09-05Corpak Medsystems, Inc.Probiotic/prebiotic composition and delivery method
DE10206995B4 (en)2002-02-192014-01-02Orthomol Pharmazeutische Vertriebs Gmbh Micronutrient combination product with pro- and prebiotics
JP2003261453A (en)2002-03-112003-09-16Nippon Berumu KkAntitumor agent and radiation-protecting agent consisting of e. faecalis
CA2490016C (en)2002-06-282017-08-22Puleva Biotech, S.A.Probiotic strains, a process for the selection of them, compositions thereof, and their use
US20040005304A1 (en)2002-07-082004-01-08Mak Wood, Inc.Novel compositions and methods for treating neurological disorders and associated gastrointestinal conditions
GB0307026D0 (en)2003-03-272003-04-30Rowett Res InstBacterial supplement
EP1481681A1 (en)2003-05-302004-12-01Claudio De SimoneLactic acid bacteria combination and compositions thereof
GB0316915D0 (en)2003-07-182003-08-20Glaxo Group LtdCompounds
WO2005007834A1 (en)2003-07-232005-01-27Probionic Corp.Acid tolerant probiotic lactobacillus plantarum probio-38 that can suppress the growth of pathogenic microorganism and tge coronavirus
US7485325B2 (en)2003-08-062009-02-03Gayle Dorothy SwainAnimal food supplement compositions and methods of use
JP4683881B2 (en)2003-08-272011-05-18有限会社アーク技研 Antitumor active
US8192733B2 (en)2003-08-292012-06-05Cobb & AssociatesProbiotic composition useful for dietary augmentation and/or combating disease states and adverse physiological conditions
WO2005030133A2 (en)2003-09-222005-04-07Yale UniversityTreatment with agonists of toll-like receptors
GB0323039D0 (en)2003-10-012003-11-05DaniscoMethod
RU2543662C2 (en)2003-10-242015-03-10Н.В. НютрисиаSynbiotic composition for children for prevention and treatment of diaper skin rash
US20050239706A1 (en)2003-10-312005-10-27Washington University In St. LouisModulation of fiaf and the gastrointestinal microbiota as a means to control energy storage in a subject
JP4850715B2 (en)2003-12-172012-01-11エヌ.ブイ.・ヌートリシア Lactic acid producing bacteria and lung function
ES2235642B2 (en)2003-12-182006-03-01Gat Formulation Gmbh CONTINUOUS MULTI-MICROENCAPSULATION PROCESS FOR THE IMPROVEMENT OF STABILITY AND STORAGE OF BIOLOGICALLY ACTIVE INGREDIENTS.
WO2005093049A1 (en)2004-03-222005-10-06Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human ServicesCellular and viral inactivation
WO2005107381A2 (en)2004-05-072005-11-17Hans-Gustaf LjunggrenUse of flagellin as an adjuvant for vaccine
PE20060426A1 (en)2004-06-022006-06-28Schering Corp TARTARIC ACID DERIVATIVES AS INHIBITORS OF MMPs, ADAMs, TACE AND TNF-alpha
US7638513B2 (en)2004-06-022009-12-29Schering CorporationCompounds for the treatment of inflammatory disorders
ES2404695T3 (en)2004-06-072013-05-28Qu Biologics Inc Bacterial compositions for the treatment of cancer
PL1629850T5 (en)2004-08-242013-09-30Nutricia NvNutritional composition comprising indigestible transgalactooligosaccharides and digestible galactose saccharides
US20060062742A1 (en)2004-09-212006-03-23The Procter & Gamble CompanyCompositions for reduction of human malodor
KR100468522B1 (en)2004-10-122005-01-31주식회사 프로바이오닉2 -63new acid tolerant probiotic enterococcus faecium probio-63 that can suppress the growth of corona virus and porcine circovirus type 2
US20060115465A1 (en)2004-10-292006-06-01Macfarlane GeorgeTreatment of gastrointestinal disorders
ITMI20042189A1 (en)2004-11-162005-02-16Anidral Srl COMPOSITION BASED ON PROBIOTIC BACTERIA AND ITS USE IN THE PREVENTION OF E-OR IN THE TREATMENT OF PATHOLOGIES AND-OR RESPIRATORY INFECTIONS AND IN THE IMPROVEMENT OF INTESTINAL FUNCTIONALITY
TR201820329T4 (en)2005-02-282019-01-21Nutricia Nv Food Composition Containing Probiotics
EP1861490A4 (en)2005-03-232010-11-17Univ St Louis USE OF ARCHAEA FOR MODULATING NUTRITIONAL FUNCTIONALITY OF GASTROINTESTINAL BIOZOOSIS
US20090233888A1 (en)2005-03-232009-09-17Usc Stevens, University Of Southern CaliforniaTreatment of disease conditions through modulation of hydrogen sulfide produced by small intestinal bacterial overgrowth
JP2006265212A (en)2005-03-252006-10-05Institute Of Physical & Chemical Research IL-21 production inducer
US20100233312A9 (en)2005-04-112010-09-16The Procter & Gamble CompanyCompositions comprising probiotic and sweetener components
EP1714660A1 (en)2005-04-212006-10-25N.V. NutriciaUronic acid and probiotics
US8603461B2 (en)2005-04-262013-12-10TEAGASC—The Agriculture and Food Development AuthorityProbiotic composition suitable for animals
CA3151350A1 (en)2005-05-092006-11-16E. R. Squibb & Sons, L.L.C.Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
US7572474B2 (en)2005-06-012009-08-11Mead Johnson Nutrition CompanyMethod for simulating the functional attributes of human milk oligosaccharides in formula-fed infants
US8075934B2 (en)2008-10-242011-12-13Mead Johnson Nutrition CompanyNutritional composition with improved digestibility
JP2007084533A (en)2005-08-242007-04-05Prima Meat Packers Ltd Immune response modulating composition and food containing the composition as an active ingredient
US7625704B2 (en)2005-08-312009-12-01Fred Hutchinson Cancer Research CenterMethods and compositions for identifying bacteria associated with bacteria vaginosis
JP2009507023A (en)2005-09-012009-02-19シェーリング コーポレイション Use of IL-23 and IL-17 antagonists to treat autoimmune ocular inflammatory diseases
EP1945234B1 (en)2005-09-232012-12-19Gwangju Institute of Science and TechnologyComposition for preventing or treating arthritis comprising lactic acid bacteria and collangen as active ingredients
EP1776877A1 (en)2005-10-212007-04-25N.V. NutriciaMethod for stimulating the intestinal flora
BRPI0617746A2 (en)2005-10-242011-08-02Nestec Sa formulation for food fiber and its use
JP2007116991A (en)2005-10-282007-05-17Eternal Light General Institute Inc Functional food
US7767420B2 (en)2005-11-032010-08-03Momenta Pharmaceuticals, Inc.Heparan sulfate glycosaminoglycan lyase and uses thereof
EP1957449A1 (en)2005-12-012008-08-20Schering CorporationCompounds for the treatment of inflammatory disorders and microbial diseases
WO2007098371A2 (en)2006-02-162007-08-30Wayne State UniversityUse of flagellin to prevent and treat gram negative bacterial infection
US20080260906A1 (en)2006-03-172008-10-23Marko StojanovicCompositions comprising probiotic and sweetener components
JP5031249B2 (en)2006-03-222012-09-19学校法人北里研究所 Bacteria-containing composition having anti-inflammatory effect
WO2007136719A2 (en)2006-05-182007-11-29Biobalance LlcBiotherapeutic compositions comprising probiotic escherichia coli and uses thereof
MX2008015031A (en)2006-05-262008-12-05Nestec SaMethods of use and nutritional compositions of touchi extract.
CA2654457A1 (en)2006-06-062007-12-13Mcgill UniversityFermented milk product and use thereof
TW200819540A (en)2006-07-112008-05-01Genelux CorpMethods and compositions for detection of microorganisms and cells and treatment of diseases and disorders
EP2845496A1 (en)2006-08-042015-03-11SHS International Ltd.Protein free formula with prebiotics
WO2008031438A2 (en)2006-09-132008-03-20Region Hovedstaden V/Gentofte HospitalTreatment of asthma, eczema and/or allergy using non-pathogenic organisms
US20080069861A1 (en)2006-09-192008-03-20National Starch And Chemical Investment Holding CorporationProbiotic/Non-Probiotic Combinations
KR20120038021A (en)2006-10-272012-04-20화이자 프로덕츠 인코포레이티드Hydroxypropyl methyl cellulose hard capsules and process of manufacture
WO2008053444A2 (en)2006-11-012008-05-08The Procter & Gamble CompanyTreating a respiratory condition with bifidobacterium
PL1920781T3 (en)2006-11-102015-06-30Glycotope GmbhCompositions comprising a core-1 positive microorganism and their use for the treatment or prophylaxis of tumors
WO2008064489A1 (en)2006-12-012008-06-05Mcmaster UniversityProbiotics to inhibit inflammation
WO2008076696A2 (en)2006-12-182008-06-26Washington University In St. LouisThe gut microbiome as a biomarker and therapeutic target for treating obesity or an obesity related disorder
DE102006062250A1 (en)2006-12-222008-06-26Roland Saur-Brosch Use of a composition of minerals and / or vitamins and optionally acetogenic and / or butyrogenic bacteria for oral or rectal administration for the treatment and prevention of abdominal discomfort
WO2008083157A2 (en)2006-12-292008-07-10Washington University In St. LouisAltering pgc-1alapha, ampk, fiaf, or the gastrointestinal microbiota as a means to modulate body fat and/or weight loss in a subject
JP2008195635A (en)2007-02-092008-08-28Crossfield Bio IncLactic acid bacteria preparation for horse
CN105796607A (en)2007-02-282016-07-27Mjn 美国控股有限责任公司Product containing inactivated probiotic for children or infants
WO2008117267A2 (en)2007-03-282008-10-02Alimentary Health LimitedProbiotic bifidobacterium strains
GB2465051B (en)2007-03-282012-01-25Alimentary Health LtdProbiotic bifidobacterium strains
JP5185996B2 (en)2007-04-242013-04-17ケミン、インダストリーズ、インコーポレーテッド Broad spectrum antibacterial and antifungal activity of Lactobacillus johnsonii D115
EP1997499A1 (en)2007-05-312008-12-03Puleva Biotech, S.A.Mammalian milk microorganisms, compositions containing them and their use for the treatment of mastitis
EP1997905A1 (en)2007-06-012008-12-03Friesland Brands B.V.Nucleic acid amplification
EP1997907A1 (en)2007-06-012008-12-03Friesland Brands B.V.Bifidobacteria
EP1997906A1 (en)2007-06-012008-12-03Friesland Brands B.V.Lactobacillus
WO2008153377A1 (en)2007-06-152008-12-18N.V. NutriciaNutrition with non-viable bifidobacterium and non-digestible oligosaccharide
EP2522358B1 (en)2007-06-272016-11-09Laboratorios Ordesa, S.l.Peptides against rotavirus infection
HUP0700552A2 (en)2007-08-272009-03-30Janos Dr FeherMethod and composition inhibiting inflammation
WO2009030254A1 (en)2007-09-042009-03-12Curevac GmbhComplexes of rna and cationic peptides for transfection and for immunostimulation
WO2009043856A2 (en)2007-10-012009-04-09University College Cork, National University Of Ireland, CorkModulation of tissue fatty acid composition of a host by human gut bacteria
DK2203551T3 (en)2007-10-202013-10-28Univ Liege BIFIDOBACTERY SPECIES
NZ585210A (en)2007-10-262012-07-27Brenda e mooreProbiotic compositions comprising bacteroides and methods for inducing and supporting weight loss
US9351992B2 (en)2007-11-022016-05-31Momenta Pharmaceuticals, Inc.Non-anticoagulant polysaccharide compositions
EP2065048A1 (en)2007-11-302009-06-03Institut PasteurUse of a L. casei strain, for the preparation of a composition for inhibiting mast cell activation
EP2217253B1 (en)2007-12-072011-06-29N.V. NutriciaBifidobacterium for dust mite allergy
WO2009079564A2 (en)2007-12-172009-06-25Emory UniversityImmunogenic compositions and methods of use thereof
ES2343499B1 (en)2007-12-242011-06-10Consejo Superior De Investigaciones Cientificas MICROORGANISMS TO IMPROVE THE STATE OF HEALTH OF INDIVIDUALS WITH DISORDERS RELATED TO THE INTAKE OF GLUTEN.
CA2713525A1 (en)2008-02-062009-08-13The Procter & Gamble CompanyCompositions methods and kits for enhancing immune response to a respiratory condition
EP2103226A1 (en)2008-03-182009-09-23Friesland Brands B.V.Long-life probiotic food product
JP2011519828A (en)2008-04-182011-07-14バクシネート コーポレーション Flagellin deletion mutants and methods of use
CA2722738C (en)2008-05-132017-04-25Glycotope GmbhFermentation process
MX2008006546A (en)2008-05-212009-11-23Sigma Alimentos Sa De CvBifidobacteria that produces folic acid, food composition and use of said bifidobacteria.
CN101590081A (en)2008-05-282009-12-02青岛东海药业有限公司 Preparations of Eubacterium protrudoides and Eubacterium dimorpha and their application
CN102940652B (en)2008-05-282015-03-25青岛东海药业有限公司Eubacterium biforme preparation and use thereof
WO2009149149A1 (en)2008-06-042009-12-10Trustees Of Dartmouth CollegePrevention or treatment of immune-relevant disease by modification of microfloral populations
EP2133088A3 (en)2008-06-092010-01-27Nestec S.A.Rooibos and inflammation
WO2009151315A1 (en)2008-06-132009-12-17N.V. NutriciaNutritional composition for infants delivered via caesarean section
WO2009154463A2 (en)*2008-06-202009-12-23Stichting Top Institute Food And NutritionButyrate as a medicament to improve visceral perception in humans
EP2138186A1 (en)2008-06-242009-12-30Nestec S.A.Probiotics, secretory IgA and inflammation
WO2010002241A1 (en)2008-06-302010-01-07N.V. NutriciaNutritional composition for infants delivered via caesarean section
KR101017448B1 (en)2008-09-182011-02-23주식회사한국야쿠르트 Bifidobacterium long gum H.Y.8004 having the health promoting effect of large intestine and product containing it as an active ingredient
US20100074870A1 (en)2008-09-192010-03-25Bristol-Myers Squibb CompanyProbiotic infant products
US8137718B2 (en)2008-09-192012-03-20Mead Johnson Nutrition CompanyProbiotic infant products
KR101057357B1 (en)2008-09-222011-08-17광주과학기술원Pharmaceutical and Food Compositions for Preventing or Treating Arthritis Comprising Lactic Acid Bacteria and Collagen as Active Ingredients
WO2010036876A2 (en)2008-09-252010-04-01New York UniversityCompositions and methods for characterizing and restoring gastrointestinal, skin, and nasal microbiota
WO2010037408A1 (en)2008-09-302010-04-08Curevac GmbhComposition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
WO2010037402A1 (en)2008-10-022010-04-08Dako Denmark A/SMolecular vaccines for infectious disease
BRPI0922296A2 (en)2008-12-052015-08-11Nestec Sa Compositions for use in low birth weight newborns.
BRPI0923171A2 (en)2008-12-192015-08-11Nestec Sa Prevention and treatment of rotavirus diarrhea.
IT1392672B1 (en)2009-01-122012-03-16Wyeth Consumer Healthcare S P A COMPOSITIONS INCLUDING PROBIOTIC COMPONENTS AND PREBIOTICS AND MINERAL SALTS, WITH LACTOFERRINA
MX2011009362A (en)2009-03-052011-09-26Abbott LabIl-17 binding proteins.
JP5710876B2 (en)2009-03-262015-04-30クロスフィールドバイオ株式会社 Novel Bifidobacterium and its utilization
WO2010129839A1 (en)2009-05-072010-11-11Tate & Lyle Ingredients France SASCompositions and methods for making alpha-(1,2)-branched alpha-(1,6) oligodextrans
EP2251022A1 (en)2009-05-112010-11-17Nestec S.A.Non-replicating micro-organisms and their immune boosting effect
CA2761444C (en)2009-05-112018-04-24Nestec S.A.Lactobacillus johnsonii la1 ncc533 (cncm i-1225) and immune disorders
EP2251020A1 (en)2009-05-112010-11-17Nestec S.A.Short-time high temperature treatment generates microbial preparations with anti-inflammatory profiles
KR20100128168A (en)2009-05-272010-12-07중앙대학교 산학협력단 New strain with excellent conjugated linoleic acid production capacity
US20100311686A1 (en)2009-06-032010-12-09Kasper Lloyd HNutraceutical composition and methods for preventing or treating multiple sclerosis
WO2010143940A1 (en)2009-06-122010-12-16N.V. NutriciaSynergistic mixture of beta-galacto-oligosaccharides with beta-1,3 and beta-1,4/1,6 linkages
WO2010147714A1 (en)2009-06-162010-12-23The Trustees Of Columbia University In The City Of New YorkAutism-associated biomarkers and uses thereof
WO2011005756A1 (en)2009-07-062011-01-13Puretech Ventures, LlcDelivery of agents targeted to microbiota niches
CA2768301A1 (en)2009-07-242011-01-27Southwest Regional Pcr, LlcUniversal microbial diagnosis, detection, quantification, and specimen-targeted therapy
US9439449B2 (en)2009-08-182016-09-13Nestec S.A.Nutritional composition comprising Bifidobacterium longum strains and reducing food allergy symptoms, especially in infants and children
US20110053829A1 (en)2009-09-032011-03-03Curevac GmbhDisulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
WO2011036539A1 (en)2009-09-232011-03-31Borody Thomas JTherapy for enteric infections
EP2308498A1 (en)2009-09-302011-04-13Nestec S.A.Administration of Bifidobacterium breve during infancy to prevent inflammation later in life
EP2486143A1 (en)2009-10-052012-08-15AAK Patent B.V.Methods for diagnosing irritable bowel syndrome
WO2011044208A1 (en)2009-10-062011-04-14Scott DorfnerAntibiotic formulations providing reduced gastrointentestinal side effects
EP2498789B1 (en)2009-11-112016-06-22Alimentary Health LimitedProbiotic bifidobacterium strain
JP2013514085A (en)2009-12-182013-04-25ヒルズ・ペット・ニュートリシャン・インコーポレーテッド Pet food compositions containing probiotics and methods of preparing and using the same
US20150104418A1 (en)2014-12-182015-04-16Microbios, Inc.Bacterial composition
FR2955774A1 (en)2010-02-022011-08-05Aragan PREPARATION FOR TREATING PONDERAL EXCES AND ASSOCIATED DISORDERS AND APPLICATIONS THEREOF
NL2004200C2 (en)2010-02-052011-08-08Friesland Brands BvUse of sialyl oligosaccharides in weight management.
NL2004201C2 (en)2010-02-052011-08-08Friesland Brands BvUse of sialyl oligosaccharides to modulate the immune system.
IT1398553B1 (en)2010-03-082013-03-01Probiotical Spa COMPOSITION INCLUDING PROBIOTIC BACTERIA FOR THE TREATMENT OF PATHOLOGIES ASSOCIATED WITH THE ALTERATION OF THE IMMUNE SYSTEM.
JP5737646B2 (en)2010-03-242015-06-17森下仁丹株式会社 Antiallergic agent
WO2011121379A1 (en)2010-03-302011-10-06Assistance Publique - Hopitaux De ParisUse of bifidobacteria for preventing allergy in breastfed infants
US8951512B2 (en)2010-05-042015-02-10New York UniversityMethods for treating bone disorders by characterizing and restoring mammalian bacterial microbiota
WO2011149335A1 (en)2010-05-252011-12-01N.V. NutriciaImmune imprinting nutritional composition
EP2585583A4 (en)2010-06-012014-01-15Moore Res Entpr LlcCellular constituents from bacteroides, compositions thereof, and therapeutic methods employing bacteroides or cellular constituents thereof
WO2011151941A1 (en)2010-06-042011-12-08国立大学法人東京大学Composition having activity of inducing proliferation or accumulation of regulatory t cell
TWI417054B (en)2010-06-152013-12-01Jen Shine Biotechnology Co LtdNovel enterococcus faecium ljs-01 and its use for probiotic
EP2397145A1 (en)2010-06-182011-12-21Nestec S.A.L. johnsonii La1, B. longum NCC2705 and immune disorders
FR2962045B1 (en)2010-07-052012-08-17Bifinove MACROMOLECULAR COMPLEX OF BACTERIAL ORIGIN AND USE OF SAID MOLECULAR COMPLEX FOR PREVENTING AND TREATING INFLAMMATORY RHUMATISMS
TWI401086B (en)2010-07-202013-07-11Univ China MedicalLactobacillus plantarum and uses thereof
NZ606490A (en)2010-07-262015-04-24Qu Biolog IncImmunogenic anti-inflammatory compositions
CA2807242C (en)2010-08-042017-05-02Thomas Julius BorodyCompositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US9386793B2 (en)2010-08-202016-07-12New York UniversityCompositions and methods for treating obesity and related disorders by characterizing and restoring mammalian bacterial microbiota
KR101250463B1 (en)2010-10-122013-04-15대한민국Oxygen tolerant Bifidobacterium longum from Korean neonate fecal samples and probiotic compositions produced by the same
CA2815259A1 (en)2010-10-272012-05-03Quantibact A/SCapture of target dna and rna by probes comprising intercalator molecules
CN102031235B (en)2010-11-092012-07-25中国农业大学Enterococcus faecium ANSE228 and application thereof
EP2455092A1 (en)2010-11-112012-05-23Nestec S.A.Non-replicating probiotic micro-organisms protect against upper respiratory tract infections
US20120128644A1 (en)2010-11-242012-05-24Oragenics, Inc.Use of Bacteria to Treat and Prevent Respiratory Infections
CN102093967B (en)2010-12-022013-01-30中国农业科学院特产研究所 A strain of Enterococcus faecium derived from mink and its application
ES2389547B1 (en)2010-12-072013-08-08Consejo Superior De Investigaciones Científicas (Csic) BIFIDOBACTERIUM CECT 7765 AND ITS USE IN THE PREVENTION AND / OR TREATMENT OF OVERWEIGHT, OBESITY AND ASSOCIATED PATHOLOGIES.
SG191830A1 (en)2011-01-102013-08-30Cleveland Biolabs IncUse of toll-like receptor agonist for treating cancer
ES2610908T3 (en)2011-01-312017-05-04Synformulas Gmbh Bifidobacterium bifidum strains for application in gastrointestinal diseases
JP5840368B2 (en)2011-02-022016-01-06カルピス株式会社 Substances for preventing and improving arthritis
CN103491969A (en)2011-02-092014-01-01拉维沃公司Synbiotic compositions for restoration and reconstitution of gut microbiota
BR112013022927A2 (en)2011-03-092016-12-06Univ Minnesota composition, methods for replacing or supplementing or modifying a subject's microbiota of the colon, and for treating a subject, and, use of a composition
BRPI1100857A2 (en)2011-03-182013-05-21Alexandre Eduardo Nowill immunomodulatory agent and combinations thereof, their use and immunotherapeutic method for real time recontextualization, reprogramming and rebuilding of the immune system
WO2012140636A1 (en)2011-04-112012-10-18Alimentary Health LimitedA probiotic formulation
WO2012142605A1 (en)2011-04-152012-10-18Samaritan Health ServicesRapid recolonization deployment agent
AP2013007242A0 (en)2011-04-202013-11-30Mico Bio IncComposition and method for enhancing an immune response
WO2012158517A1 (en)2011-05-132012-11-22Glycosyn LLCThe use of purified 2'-fucosyllactose, 3-fucosyllactose and lactodifucotetraose as prebiotics
KR20120133133A (en)2011-05-302012-12-10한국 한의학 연구원Composition for Prevention or Treatment of Respiratory Disease Comprising Herbal Extract and Fermentation Product thereof with Lactic acid Bacteria
WO2012170478A2 (en)2011-06-062012-12-13The University Of North Carolina At Chapel HillMethods and kits for detecting adenomas, colorectal cancer, and uses thereof
GB201110095D0 (en)2011-06-152011-07-27DaniscoMethod of treatment
JP2013005759A (en)2011-06-242013-01-10Kyodo Milk Industry Co LtdMethod for estimating intestinal bacterial flora of mouse
US20140128585A1 (en)2011-07-072014-05-08Nagaoka Perfumery Co., Ltd.Fructose absorption inhibitor
GB201112091D0 (en)2011-07-142011-08-31Gt Biolog LtdBacterial strains isolated from pigs
US20130017999A1 (en)2011-07-142013-01-17Marc FremontMethods and Compositions for Evaluating and/or Treating Chronic Immune Diseases
US20130022575A1 (en)2011-07-192013-01-24Microbial RxSystems and methods of replacing intestinal flora
CN102304483A (en)2011-08-122012-01-04北京金泰得生物科技股份有限公司Enterococcus faecium for feeding and applications thereof
KR101261872B1 (en)2011-08-232013-05-14대한민국 (식품의약품안전처장)A intestinal microbial enzyme mixture and it's preparation thereof
ES2662793T3 (en)2011-09-142018-04-09Nubiyota Llc Media supplements and methods for growing human gastrointestinal anaerobic microorganisms
GB201117313D0 (en)2011-10-072011-11-16Gt Biolog LtdBacterium for use in medicine
EP2750682B1 (en)2011-10-112016-05-18Achim Biotherapeutics ABComposition comprising anaerobically cultivated human intestinal microbiota
CN103082292B (en)2011-11-022015-03-04深圳华大基因研究院Use of Roseburia for the treatment and prevention of obesity-related diseases
CN102373172B (en)2011-11-032013-03-20北京龙科方舟生物工程技术有限公司Enterococcus faecium and application thereof
CN108676774B (en)2011-12-012023-05-09国立大学法人东京大学 Human-derived bacteria that induce the proliferation or accumulation of regulatory T cells
ES2408279B1 (en)2011-12-152014-09-09Universidad De Las Palmas De Gran Canaria PROBIOTIC LACTIC ACID BACTERIA
ITBG20120010A1 (en)2012-02-242013-08-25Milano Politecnico DEVICE FOR SURGICAL TRAINING
ITMI20120471A1 (en)2012-03-262013-09-27Giovanni Mogna COMPOSITION BASED ON BACTERIA BIFID BACTERIUM LONGUM STRIPS ABLE TO HELP THE EXTENSION OF LIFE
JP5792105B2 (en)2012-03-272015-10-07森永乳業株式会社 Method for producing lacto-N-biose I
WO2013146319A1 (en)2012-03-302013-10-03味の素株式会社Diabetes-inducible bacterium
WO2013154826A2 (en)2012-04-112013-10-17Nestec SaMethods for diagnosing impending diarrhea
GB201206599D0 (en)2012-04-132012-05-30Univ ManchesterProbiotic bacteria
JP2015512936A (en)2012-04-132015-04-30トラスティーズ オブ ボストン カレッジ Prebiotic composition and method of use thereof
EP3686284A1 (en)2012-05-182020-07-29Genome Research LimitedMethods and groups
ES2436251B1 (en)2012-05-252014-10-08Consejo Superior De Investigaciones Científicas (Csic) BACTEROIDS CECT 7771 AND ITS USE IN THE PREVENTION AND TREATMENT OF OVERWEIGHT, OBESITY AND METABOLIC AND IMMUNOLOGICAL ALTERATIONS.
CN110170050A (en)2012-06-042019-08-27高拉夫·阿格拉沃尔 Compositions and methods for treating Crohn's disease and related conditions and infections
CN102743420A (en)2012-06-062012-10-24上海交通大学 Method and application of improving intestinal flora structure
WO2014001368A1 (en)2012-06-252014-01-03Orega BiotechIl-17 antagonist antibodies
EP2879523B1 (en)2012-07-312016-11-16Nestec S.A.Nutritional composition for promoting musculoskeletal health in patients with inflammatory bowel disease (ibd)
WO2014019271A1 (en)2012-08-012014-02-06Bgi ShenzhenBiomarkers for diabetes and usages thereof
WO2014036182A2 (en)2012-08-292014-03-06California Institute Of TechnologyDiagnosis and treatment of autism spectrum disorder
CA2882316A1 (en)2012-08-292014-03-06Salix Pharmaceuticals, Inc.Laxative compositions and methods for treating constipation and related gastrointestinal diseases and conditions
EP2894985A4 (en)2012-09-132016-09-28Massachusetts Inst Technology PROGRAMMABLE MEDICATION DELIVERY PROFILES OF TUMOR TARGETED BACTERIA
KR101473058B1 (en)2012-09-192014-12-16주식회사 쎌바이오텍Composition for preventing or treating irritable bowel syndrome
CN103652322B (en)2012-09-212016-02-10临沂思科生物科技有限公司A kind of preparation method of lactobacteria-containing composite probiotics feed additive
EP3401396A1 (en)2012-10-032018-11-14Metabogen ABTreating or preventing atherosclerosis or associated diseases by beta-carotene
FR2997091B1 (en)2012-10-222016-05-06Fond Mediterranee Infection USE OF ANTIOXIDANT COMPOUND FOR THE CULTURE OF BACTERIA SENSITIVE TO OXYGEN TENSION
US20150290140A1 (en)2012-10-302015-10-15Nestec S.A.Compositions comprising microparticles and probiotics to deliver a synergistic immune effect
WO2014070225A1 (en)2012-10-302014-05-08Deerland Enzymes, Inc.Prebiotic compositions comprising one or more types of bacteriophage
US20150283144A1 (en)2012-11-012015-10-08Rijksuniversiteit GroningenMethods and compositions for stimulating beneficial bacteria in the gastrointestinal tract
WO2014075745A1 (en)2012-11-192014-05-22Université Catholique de LouvainUse of akkermansia for treating metabolic disorders
US8906668B2 (en)2012-11-232014-12-09Seres Health, Inc.Synergistic bacterial compositions and methods of production and use thereof
AU2013347805C1 (en)2012-11-232018-06-28Seres Therapeutics, Inc.Synergistic bacterial compositions and methods of production and use thereof
CA2896795A1 (en)2012-11-262014-05-30Thomas Julius BorodyCompositions for the restoration of a fecal microbiota and methods for making and using them
IL293526A (en)2012-12-122022-08-01Harvard College Providing, engineering and optimizing systems, methods and compositions for sequence manipulation and therapeutic applications
WO2014093655A2 (en)2012-12-122014-06-19The Broad Institute, Inc.Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains
ES2576126T3 (en)2012-12-122016-07-05The Broad Institute, Inc. Modification by genetic technology and optimization of improved enzyme systems, methods and compositions for sequence manipulation
US20140193464A1 (en)2013-01-082014-07-10Imagilin Technology, LlcEffects of probiotics on humans and animals under environmental or biological changes
AU2014212003C1 (en)2013-02-042020-07-16Seres Therapeutics, Inc.Compositions and methods for inhibition of pathogenic bacterial growth
EP2951283A4 (en)2013-02-042017-01-25Seres Therapeutics, Inc.Compositions and methods
US10028983B2 (en)2013-02-222018-07-24The Regents Of The University Of CaliforniaCompositions and methods for promoting growth of beneficial microbes to treat or prevent disease or prolong life
CN105228635A (en)2013-03-052016-01-06格罗宁根大学Faecalibacterium prausnitzii HTF-F(DSM 26943) application in inflammation-inhibiting
CA3013541C (en)2013-03-142021-01-19Therabiome, LlcTargeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents
EP2971148A4 (en)2013-03-142016-08-17Seres Therapeutics IncMethods for pathogen detection and enrichment from materials and compositions
AU2014232370B2 (en)2013-03-152018-11-01Société des Produits Nestlé S.A.Network-based microbial compositions and methods
US9669059B2 (en)2013-03-152017-06-06University Of Florida Research Foundation, IncorporatedButyrogenic bacteria as probiotics to treat clostridium difficile
CN103142656A (en)2013-03-182013-06-12广州知光生物科技有限公司Application of bacteroides fragilis in preparing composition for preventing and treating colon cancer
CN103156888A (en)2013-03-182013-06-19广州知光生物科技有限公司Application of bacteroides fragilis in preparation of composition for treating inflammatory bowel diseases
CN103146620A (en)2013-03-252013-06-12广州知光生物科技有限公司Bacteroides fragilis with characteristics of probiotics
JP2014196260A (en)2013-03-292014-10-16公立大学法人奈良県立医科大学Preventive or therapeutic composition of chronic obstructive pulmonary disease
GB201306536D0 (en)2013-04-102013-05-22Gt Biolog LtdPolypeptide and immune modulation
WO2014182966A1 (en)2013-05-102014-11-13California Institute Of TechnologyProbiotic prevention and treatment of colon cancer
WO2014197562A1 (en)2013-06-052014-12-11Rebiotix, Inc.Microbiota restoration therapy (mrt), compositions and methods of manufacture
US9511099B2 (en)2013-06-052016-12-06Rebiotix, Inc.Microbiota restoration therapy (MRT), compositions and methods of manufacture
WO2014201037A2 (en)*2013-06-102014-12-18New York UniversityMethods for manipulating immune responses by altering microbiota
WO2014200334A1 (en)2013-06-142014-12-18N.V. NutriciaSynbiotic composition for treatment of infections in allergic patients
WO2015003001A1 (en)2013-07-012015-01-08The Washington UniversityMethods for identifying supplements that increase gut colonization by an isolated bacterial species, and compositions derived therefrom
WO2015003305A1 (en)2013-07-082015-01-15吉瑞高新科技股份有限公司Electronic cigarette case
US9764019B2 (en)2013-07-092017-09-19Vedanta Biosciences, Inc.Compositions containing combinations of bioactive molecules derived from microbiota for treatment of disease
US10633714B2 (en)2013-07-212020-04-28Pendulum Therapeutics, Inc.Methods and systems for microbiome characterization, monitoring and treatment
WO2015017625A1 (en)2013-07-312015-02-05Wikifoods, Inc.Encapsulated functional food compositions
WO2015021936A1 (en)2013-08-162015-02-19The University Of Hong KongMethod and compositions for treating cancer using probiotics cross-reference to related application
CN103509741B (en)2013-08-222015-02-18河北农业大学Braun bacterium AUH-JLD56 and application thereof in arctigenin conversion
US10203329B2 (en)2013-09-122019-02-12The Johns Hopkins UniversityBiofilm formation to define risk for colon cancer
WO2015057151A1 (en)2013-10-182015-04-23Innovafood AbA nutritionally balanced composite meal for infants and small children and a method of producing said meal
PL229020B1 (en)2013-11-132018-05-30Inst Biotechnologii Surowic I Szczepionek Biomed Spolka AkcyjnaNew strain of Bifidobacterium breve
WO2015077794A1 (en)2013-11-252015-05-28Seres Health, Inc.Synergistic bacterial compositions and methods of production and use thereof
EP3082431A4 (en)2013-12-162017-11-15Seres Therapeutics, Inc.Bacterial compositions and methods of use thereof for treatment of immune system disorders
CN103981117B (en)2013-12-242018-10-26北京大伟嘉生物技术股份有限公司One plant height resistance enterococcus faecium and its cultural method and application
CN103981115B (en)2013-12-242018-10-26北京大伟嘉生物技术股份有限公司One plant height resistance enterococcus faecium and its application
CN103820363B (en)2014-01-272016-02-24福建省农业科学院生物技术研究所A kind of preparation and application of faecium bacterium powder
CN103865846B (en)2014-02-272016-03-30扬州绿保生物科技有限公司A kind of faecium and preparation method thereof
CN103849590B (en)2014-03-252016-07-06上海交通大学The one acidproof bifidobacterium breve BB8dpH of strain and application thereof
KR101683474B1 (en)2014-03-262016-12-08주식회사 쎌바이오텍Composition for preventing or treating irritable bowel syndrome
US9783858B2 (en)2014-04-022017-10-10Northwestern UniversityAltered microbiome of chronic pelvic pain
KR101583546B1 (en)2014-04-092016-01-11국립암센터Method for prediction of reactivity to sorafenib treatment Using gene polymorphism
MX387331B (en)2014-04-102025-03-18Riken COMPOSITIONS AND METHODS FOR INDUCTION OF TH17 CELLS.
CN104195075B (en)2014-08-142017-04-19生合生物科技股份有限公司 A kind of Enterococcus faecium EF08 and its feed additive and feed
WO2015168534A1 (en)2014-05-022015-11-05Novogy, Inc.Therapeutic treatment of gastrointestinal microbial imbalances through competitive microbe displacement
EP3139914B1 (en)2014-05-082023-07-26Kiora Pharmaceuticals GmbHCompounds for treating ophthalmic diseases and disorders
CN106687130B (en)2014-08-052020-01-21深圳华大基因科技有限公司Use of eubacterium for preventing and treating colorectal cancer-related diseases
EP3453396A1 (en)2014-08-282019-03-13Yale UniversityCompositions and methods for treating an inflammatory disease or disorder
WO2016036615A1 (en)2014-09-032016-03-10California Institute Of TechnologyMicrobe-based modulation of serotonin biosynthesis
CN104546932A (en)2014-09-302015-04-29深圳华大基因科技有限公司Application of bacteroides ovatus in treating or preventing rheumatoid arthritis or related diseases thereof
CN104546933A (en)2014-09-302015-04-29深圳华大基因科技有限公司Application of bacteroides caccae in treatment or prevention of rheumatoid arthritis or related diseases thereof
CN104546935A (en)2014-09-302015-04-29深圳华大基因科技有限公司Application of bacteroides thetaiotaomicron in treating or preventing rheumatoid arthritis or related diseases thereof
CN104546942A (en)2014-09-302015-04-29深圳华大基因科技有限公司Application of bacteroides dorei in treating or preventing rheumatoid arthritis or related diseases thereof
CN104546934B (en)2014-09-302019-04-09深圳华大基因科技有限公司 Application of Parabacteroides faecalis in the treatment or prevention of rheumatoid arthritis or its related diseases
CN104546940A (en)2014-09-302015-04-29深圳华大基因科技有限公司Application of common bacteroides in treatment or prevention of rheumatoid arthritis or related diseases thereof
WO2016057671A1 (en)2014-10-072016-04-14University Of Virginia Patent FoundationCompositions and methods for preventing and treating infection
CN107249611A (en)2014-10-242017-10-13进化生物系统股份有限公司 Activated bifidobacteria and methods of use thereof
WO2016069795A2 (en)2014-10-302016-05-06California Institute Of TechnologyCompositions and methods comprising bacteria for improving behavior in neurodevelopmental disorders
KR102511878B1 (en)2014-10-302023-03-20캘리포니아 인스티튜트 오브 테크놀로지Compositions and methods comprising bacteria for improving behavior in neurodevelopmental disorders
CN113730442A (en)2014-10-312021-12-03潘德勒姆治疗公司Methods and compositions relating to microbial treatment and diagnosis of disorders
CN104435000A (en)2014-11-122015-03-25江南大学Application of lactic acid bacteria for treating bronchial asthma
FI3223835T3 (en)2014-11-252025-06-16Memorial Sloan Kettering Cancer CenterIntestinal microbiota and gvhd
MA41020A (en)2014-11-252017-10-03Evelo Biosciences Inc PROBIOTIC AND PREBIOTIC COMPOSITIONS, AND THEIR METHODS OF USE FOR MODULATION OF THE MICROBIOME
SG10201913609PA (en)2014-12-232020-03-304D Pharma Res LtdImmune modulation
SMT201800291T1 (en)2014-12-232018-07-174D Pharma Res LimitedPirin polypeptide and immune modulation
CN104560820B (en)2014-12-302017-10-20杭州师范大学VREF KQ2.6 and application
CN107405321A (en)2015-01-232017-11-28坦普尔大学 Application of short-chain fatty acids in cancer prevention
US9878177B2 (en)*2015-01-282018-01-30Elekta Ab (Publ)Three dimensional localization and tracking for adaptive radiation therapy
CN105982919A (en)2015-02-262016-10-05王汉成Biological retarder anti-cancer technology
WO2016139217A1 (en)2015-03-042016-09-09Ab-Biotics, S.A.Composition comprising anaerobically cultivated human intestinal microbiota
WO2016149449A1 (en)2015-03-182016-09-22Tufts UniversityCompositions and methods for preventing colorectal cancer
EP3270938A4 (en)2015-03-182018-12-19Whole Biome Inc.Methods and compositions relating to microbial treatment and diagnosis of skin disorders
EP3303401B1 (en)2015-06-012024-10-16The University of ChicagoTreatment of cancer by manipulation of commensal microflora
RS59446B1 (en)2015-06-152019-11-294D Pharma Res LtdBlautia stercosis and wexlerae for use in treating inflammatory and autoimmune diseases
MA41010B1 (en)2015-06-152020-01-314D Pharma Res Ltd Compositions comprising bacterial strains
EP3360559B1 (en)2015-06-152019-10-234D Pharma Research LimitedCompositions comprising bacterial strains
MA41060B1 (en)2015-06-152019-11-294D Pharma Res Ltd Compositions comprising bacterial strains
SMT201900539T1 (en)2015-06-152019-11-134D Pharma Res LimitedCompositions comprising bacterial strains
CN105112333A (en)2015-08-312015-12-02江南大学Bifidobacterium longum with good intestinal tract colonizing ability and screening method and application of bifidobacterium longum
GB201520497D0 (en)2015-11-202016-01-064D Pharma Res LtdCompositions comprising bacterial strains
CA3005781C (en)2015-11-202019-01-224D Pharma Research LimitedCompositions comprising bacterial strains
GB201520638D0 (en)2015-11-232016-01-064D Pharma Res LtdCompositions comprising bacterial strains
GB201520631D0 (en)2015-11-232016-01-064D Pharma Res LtdCompositions comprising bacterial strains
EP3379935A4 (en)2015-11-252019-08-28Memorial Sloan-Kettering Cancer Center METHODS AND COMPOSITIONS FOR REDUCING ENTEROCOCCI INFECTION OR COLONIZATION
CA3016179C (en)2016-03-042019-08-134D Pharma PlcCompositions comprising bacterial blautia strains for treating visceral hypersensitivity
TWI802545B (en)2016-07-132023-05-21英商4D製藥有限公司Compositions comprising bacterial strains
GB201621123D0 (en)2016-12-122017-01-254D Pharma PlcCompositions comprising bacterial strains
WO2018112363A1 (en)2016-12-162018-06-21Evelo Biosciences, Inc.Methods of treating cancer using parabacteroides
WO2018112365A2 (en)2016-12-162018-06-21Evelo Biosciences, Inc.Methods of treating colorectal cancer and melanoma using parabacteroides goldsteinii
TW201907931A (en)2017-05-242019-03-01英商4D製藥研究有限公司 Composition comprising a bacterial strain

Also Published As

Publication numberPublication date
CA3016179A1 (en)2017-09-08
DK3313423T3 (en)2019-05-20
CN108883139B (en)2022-04-26
US10086022B2 (en)2018-10-02
CN108883139A (en)2018-11-23
SI3313423T1 (en)2019-07-31
SG11201807195VA (en)2018-09-27
KR20180105724A (en)2018-09-28
AU2018229410B2 (en)2020-01-02
WO2017148596A1 (en)2017-09-08
AU2017226831B2 (en)2018-10-04
CA3016179C (en)2019-08-13
MX2020005772A (en)2020-08-20
IL261371B (en)2020-01-30
MA42560B1 (en)2019-07-31
CY1122142T1 (en)2020-11-25
JP2019048857A (en)2019-03-28
ES2731579T3 (en)2019-11-18
PL3313423T3 (en)2019-09-30
HK1246670B (en)2020-05-15
CN114712405A (en)2022-07-08
HRP20191096T1 (en)2019-09-20
US10086023B2 (en)2018-10-02
TW201733601A (en)2017-10-01
US10583158B2 (en)2020-03-10
AU2017226831A1 (en)2018-09-13
RS58869B1 (en)2019-08-30
IL271536A (en)2020-02-27
EP3520801A1 (en)2019-08-07
MX373290B (en)2020-06-18
JP2022116309A (en)2022-08-09
US20180369294A1 (en)2018-12-27
MX2018010680A (en)2019-06-13
ME03487B (en)2020-01-20
NZ745678A (en)2019-03-29
CO2018010459A2 (en)2018-12-14
JP7160333B2 (en)2022-10-25
US20180221421A1 (en)2018-08-09
HUE044051T2 (en)2019-09-30
JP6441536B2 (en)2018-12-19
LT3313423T (en)2019-06-25
IL261371A (en)2018-10-31
US20180214496A1 (en)2018-08-02
EP3313423B1 (en)2019-04-24
EP3313423A1 (en)2018-05-02
EA035949B1 (en)2020-09-04
PT3313423T (en)2019-07-10
MA42560A (en)2018-05-02
MD3313423T2 (en)2019-10-31
AU2018229410A1 (en)2018-09-27
JP2018534235A (en)2018-11-22
US20220257667A1 (en)2022-08-18
KR102010207B1 (en)2019-08-12
BR112018067689A2 (en)2019-01-08
IL271536B (en)2021-08-31
SMT201900368T1 (en)2019-09-09
EA201891970A1 (en)2018-12-28

Similar Documents

PublicationPublication DateTitle
IL271536B (en)Compositions comprising bacterial blautia strains for treating visceral hypersensitivity
IL279978B (en)Compositions comprising bacterial strains
IL276288A (en)Compositions comprising bacterial strains
IL272343A (en)Compositions comprising bacterial strains
IL259024B (en)Compositions comprising bacterial strains
IL258967B (en)Compositions comprising bacterial strains
IL255783A (en)Compositions comprising bacterial strains
SG10201912319SA (en)Compositions comprising bacterial strains
GB201520631D0 (en)Compositions comprising bacterial strains
GB201616022D0 (en)Compositions comprising bacterial strains
GB201616016D0 (en)Compositions comprising bacterial strains
GB201616018D0 (en)Compositions comprising bacterial strains
GB201604920D0 (en)Compositions comprising bacterial strains
GB201604924D0 (en)Compositions comprising bacterial strains
GB201604566D0 (en)Compositions comprising bacterial strains
GB201603786D0 (en)Compositions comprising bacterial strains
GB201603817D0 (en)Compositions comprising bacterial strains

[8]ページ先頭

©2009-2025 Movatter.jp